Research shows that Lactiplantibacillus plantarum Q180, a specific probiotic strain, significantly reduced fat accumulation in the liver and improved liver damage markers in mice fed a high-fat diet, according to Gram Research analysis. The probiotic worked by reducing gut inflammation and strengthening the intestinal barrier, which prevented harmful bacterial toxins from entering the bloodstream. While these results are promising, human studies are needed before this probiotic can be recommended for preventing fatty liver disease in people.
According to Gram Research analysis, a specific probiotic called Lactiplantibacillus plantarum Q180 may help prevent fatty liver disease caused by eating too much fatty food. In a study with mice, researchers found that this probiotic reduced fat buildup in the liver and improved the gut-liver connection—the pathway between your digestive system and liver. The probiotic worked by reducing inflammation in the gut and strengthening the intestinal barrier, which normally keeps harmful substances from entering the bloodstream. While the mice still gained weight from the high-fat diet, their livers stayed healthier. These findings suggest this probiotic could become a useful tool for preventing fatty liver disease in people, though more research is needed.
Key Statistics
A 2026 research article found that Lactiplantibacillus plantarum Q180 significantly decreased hepatic triglyceride levels and improved liver damage scores in mice fed a high-fat diet, even though the mice continued to gain weight.
According to a 2026 study in the Journal of Medicinal Food, the probiotic Q180 markedly suppressed inflammatory markers TNF-α and IL-6 in the colon and significantly reduced serum endotoxin levels in high-fat diet-fed mice.
A 2026 animal study demonstrated that Q180 upregulated protective antioxidant genes in the liver while partially restoring intestinal barrier proteins (Zo-1, Occludin, and Muc2) that normally prevent harmful substances from crossing into the bloodstream.
The Quick Take
- What they studied: Whether a specific probiotic (a type of beneficial bacteria) could prevent fatty liver disease when people eat a high-fat diet
- Who participated: Male laboratory mice were divided into groups: some ate normal food, others ate a high-fat diet, and some ate high-fat food plus received the probiotic Q180 for 8 weeks
- Key finding: The probiotic significantly reduced fat in the liver and improved liver health markers, even though the mice still gained weight from the fatty diet
- What it means for you: This research suggests that taking this specific probiotic might help protect your liver from damage caused by eating fatty foods, though human studies are still needed to confirm this works in people
The Research Details
Researchers used laboratory mice to test whether a probiotic called Lactiplantibacillus plantarum Q180 could prevent fatty liver disease. They divided mice into groups: one group ate normal food, another ate a high-fat diet (60% fat), and a third group ate the high-fat diet but also received the probiotic as an oral supplement starting in week 5 and continuing for 8 weeks.
The scientists measured many things to understand what happened: they looked at how much fat accumulated in the liver, checked inflammation markers in the gut and blood, examined the strength of the intestinal barrier (the protective lining of your digestive system), and measured harmful substances called endotoxins that can leak from the gut into the bloodstream.
This type of study is called a preclinical or animal model study. It’s an important first step before testing treatments in humans because it allows researchers to carefully control all conditions and measure detailed biological changes that would be difficult to study in people.
Animal studies like this are valuable because they help researchers understand the exact biological mechanisms—the step-by-step processes—of how a treatment works. By using mice, scientists can measure liver tissue directly, examine gut bacteria changes, and test specific biological markers that would be invasive to measure in humans. This detailed information helps determine whether a probiotic is worth testing in human clinical trials.
This study was published in the Journal of Medicinal Food, a peer-reviewed scientific journal, meaning other experts reviewed the research before publication. The researchers used a standard laboratory mouse strain (C57BL/6J) that’s commonly used in nutrition research, making results comparable to other studies. However, because this is an animal study, results may not directly translate to humans—our digestive systems and metabolism are more complex. The study did not specify the exact number of mice used in each group, which would help readers understand the statistical strength of the findings.
What the Results Show
The probiotic Q180 significantly reduced the amount of fat stored in the liver. Mice that received the probiotic had much lower levels of triglycerides (a type of fat) in their liver tissue compared to mice that only ate the high-fat diet without the probiotic. The researchers also used a scoring system called the NAFLD Activity Score (NAS) to measure liver damage, and this score improved substantially in mice receiving the probiotic.
The probiotic improved three specific types of liver damage: steatosis (fat accumulation), hepatocellular ballooning (when liver cells swell up from fat), and inflammatory infiltration (when immune cells invade the liver tissue). These improvements happened even though the mice receiving the probiotic still gained weight and accumulated body fat just like the other high-fat diet mice—showing that the probiotic specifically protected the liver rather than preventing weight gain.
At the molecular level, the probiotic changed how genes were expressed in the liver. It increased production of two protective proteins: one that helps prevent fat accumulation and another that protects against oxidative stress (cellular damage from harmful molecules). Meanwhile, it decreased production of a protein involved in taking up cholesterol, which may have contributed to the protective effect.
In the colon (large intestine), the probiotic dramatically reduced inflammation by lowering levels of two inflammatory signaling molecules called TNF-α and IL-6. The probiotic also partially restored three important proteins that make up the intestinal barrier: Zo-1, Occludin, and Muc2. These proteins act like a protective fence that prevents harmful bacteria and toxins from crossing from the gut into the bloodstream.
The probiotic reduced serum endotoxin levels (harmful bacterial products in the blood) significantly, and showed a decreasing trend in fecal endotoxin levels (in stool). This is important because endotoxins that leak from the gut into the bloodstream can trigger inflammation throughout the body and contribute to liver disease.
This research builds on growing evidence that the gut-liver axis—the communication pathway between digestive health and liver function—plays a crucial role in fatty liver disease. Previous studies have suggested that probiotics might help, but this is one of the first studies to specifically test whether Q180 can prevent fatty liver disease during its early stages. The finding that the probiotic improved liver health without reducing body weight is particularly interesting because it suggests the protective mechanism works through gut and immune system improvements rather than simple weight loss.
This study used laboratory mice, not humans, so results may not directly apply to people. The study did not specify how many mice were in each group, making it difficult to assess the statistical power of the findings. The research only tested one specific probiotic strain (Q180) at one dose, so we don’t know if other probiotics would work similarly or if different doses would be more or less effective. The study lasted 12 weeks total (with probiotic treatment for 8 weeks), which is relatively short—we don’t know if benefits would continue or change over longer periods. Finally, the study didn’t measure whether the probiotic would help mice that already had established fatty liver disease, only whether it could prevent it from developing.
The Bottom Line
Based on this research, Q180 shows promise as a preventive tool for fatty liver disease, but it’s too early to recommend it for human use. The evidence is currently limited to animal studies. If you’re concerned about fatty liver disease, the most proven approaches remain: eating a balanced diet lower in processed foods and added fats, exercising regularly, and maintaining a healthy weight. If you’re interested in probiotics, talk with your doctor about whether they might be appropriate for you, as different people may benefit from different strains.
This research is most relevant to people at risk for fatty liver disease, including those who are overweight, have metabolic syndrome, or eat a high-fat diet. It’s also important for researchers and pharmaceutical companies developing new treatments for liver disease. However, because this is an animal study, people should not start taking this specific probiotic based on this research alone. Healthcare providers and researchers should care because it identifies a promising candidate for human clinical trials.
In the mouse study, improvements in liver health appeared after 8 weeks of probiotic treatment. If this translates to humans, benefits might take several weeks to months to develop. However, this is speculative—human studies would need to be conducted to determine realistic timelines for seeing benefits in people.
Frequently Asked Questions
Can probiotics help prevent fatty liver disease?
Research suggests certain probiotics like Lactiplantibacillus plantarum Q180 may help prevent fatty liver disease by reducing gut inflammation and strengthening the intestinal barrier. However, current evidence comes from animal studies; human clinical trials are needed before recommendations can be made.
What is the gut-liver axis and why does it matter?
The gut-liver axis is the communication pathway between your digestive system and liver. When your intestinal barrier weakens, harmful bacterial toxins leak into the bloodstream and trigger liver inflammation. A healthy gut barrier protects your liver from this damage.
Does this probiotic help with weight loss?
In the study, Q180 did not reduce body weight or fat tissue accumulation in mice eating a high-fat diet. However, it specifically protected the liver from fat buildup, suggesting it works through immune and inflammation pathways rather than affecting overall weight.
When can I start taking this probiotic for liver health?
This specific probiotic strain (Q180) is not yet available for human use and hasn’t been tested in clinical trials with people. Consult your doctor before taking any probiotic supplement, as different strains have different effects and may not be appropriate for everyone.
What’s the difference between this study and human research?
This animal study allowed researchers to measure detailed liver changes and gut bacteria effects that would be difficult to study in humans. However, mouse metabolism differs from human metabolism, so results must be confirmed in human clinical trials before practical recommendations can be made.
Want to Apply This Research?
- Track weekly liver health markers if available through medical testing (ALT and AST liver enzymes, triglyceride levels), or monitor dietary fat intake (grams of fat per day) and weekly weight to correlate with any probiotic supplementation
- If your doctor approves, users could log daily probiotic intake alongside dietary choices, creating a correlation tracker between probiotic consumption, high-fat food intake, and any available liver health markers from periodic blood tests
- Establish a monthly check-in system where users log their diet quality (percentage of meals that are high-fat), probiotic adherence, and any available health metrics, creating a 3-6 month trend analysis to assess personal response
This research is based on an animal study and has not been tested in humans. Lactiplantibacillus plantarum Q180 is not currently approved for human use or available as a commercial supplement. Do not start any probiotic supplement without consulting your healthcare provider, especially if you have liver disease, take medications, or have a compromised immune system. This article is for educational purposes and should not replace professional medical advice. If you have concerns about fatty liver disease, consult a qualified healthcare provider for personalized evaluation and treatment recommendations.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.